Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santarus PPI could be future Merck switch

This article was originally published in The Tan Sheet

Executive Summary

Merck's Schering-Plough consumer products unit would have OTC switch rights to a Santarus dual-buffer prescription proton pump inhibitor if FDA approves it under the Zegerid brand. The agency approved Santarus' immediate-release omeprazole/sodium bicarbonate/magnesium hydroxide prescription drug for treatment of heartburn and other symptoms of gastroesophageal reflex disease in 20-mg and 40-mg doses, the San Diego firm said Dec. 4. If FDA approves a new drug application supplement requesting the drug's name include the Zegerid brand, as Santarus expects, Merck can apply to switch it to OTC, a Santarus spokeswoman said. The Rx announcement follows FDA's approval of Zegerid OTC, set to launch in 2010 (1"The Tan Sheet" Dec. 7, 2009)
Advertisement

Related Content

Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now
Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now

Topics

Advertisement
UsernamePublicRestriction

Register

PS103624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel